Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M178Revenue $M7.2Net Margin (%)-1,236.1Z-Score-1.3
Enterprise Value $M-4.6EPS $-1.0Operating Margin %-1,240.8F-Score3
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-1,236.1Higher ROA y-yN
Price/Book1.110-y EBITDA Growth Rate %0Quick Ratio17.6Cash flow > EarningsY
Price/Sales30.95-y EBITDA Growth Rate %0Current Ratio17.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-39.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-42.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M87.5ROI % (ttm)-45.0Gross Margin Increase y-yN

Gurus Latest Trades with RIGL

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RIGLCharles Brandes 2014-03-31 Buy $2.7 - $4.75
($3.53)
$ 2-43%New holding, 15000 sh.15,000
RIGLGeorge Soros 2011-12-31 Sold Out -0.0019%$6.68 - $8.3
($7.59)
$ 2-74%Sold Out0
RIGLJean-Marie Eveillard 2011-06-30 Sold Out $7.18 - $9.19
($8.08)
$ 2-75%Sold Out0
RIGLGeorge Soros 2011-06-30 Buy $7.18 - $9.19
($8.08)
$ 2-75%New holding, 14500 sh.14,500
RIGLJean-Marie Eveillard 2011-03-31 Buy $6.54 - $7.74
($7.06)
$ 2-72%New holding, 46700 sh.46,700
RIGLGeorge Soros 2010-09-30 Sold Out $6.94 - $8.8
($8.11)
$ 2-75%Sold Out0
RIGLGeorge Soros 2010-03-31 Add$7.41 - $9.83
($8.55)
$ 2-77%Add 34.29%14,100
RIGLGeorge Soros 2009-12-31 Buy $6.08 - $9.86
($7.86)
$ 2-75%New holding, 10500 sh.10,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RIGL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RIGL Charles Brandes 2014-06-3015,0000.020
Premium Most recent portfolio changes are included for Premium Members only!


RIGL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-09-03Sell20,000$2.56-21.88view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-02-24Sell20,000$3.71-46.09view
BVF PARTNERS L P/IL10% Owner 2013-11-19Sell484,622$2.64-24.24view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy32,700$3.47-42.36view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2012-09-13Sell4,151$10.43-80.82view
Maynard Ryan DEVP & CFO 2012-09-12Sell23,302$10.67-81.26view
Maynard Ryan DEVP & CFO 2012-09-10Sell51,698$10.54-81.02view
Maynard Ryan DEVP & CFO 2012-08-07Sell1,700$10.61-81.15view
PAYAN DONALD GEVP, Pres. Discovery&Research 2012-06-19Sell10,000$8.7-77.01view
Flynn James E 2011-05-26Buy650,000$8-75view

Press Releases about RIGL :

    Quarterly/Annual Reports about RIGL:

    News about RIGL:

    Articles On GuruFocus.com
    Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

    More From Other Websites
    RIGEL PHARMACEUTICALS INC Financials Aug 15 2014
    Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Aug 14 2014
    Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today Aug 13 2014
    Rigel eye drug fails mid-stage study, shares fall Aug 13 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
    Rigel experimental eye drug fails mid-stage study Aug 13 2014
    R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study Aug 13 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2014
    Rigel Announces Second Quarter 2014 Financial Results Aug 05 2014
    Q2 2014 Rigel Pharmaceuticals Inc. Earnings Release - Before Market Open Aug 05 2014
    Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program Jul 17 2014
    Rigel Initiates Phase 3 Studies of Fostamatinib in ITP Jul 16 2014
    Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP Jul 16 2014
    Rigel to Present at Jefferies 2014 Global Healthcare Conference May 29 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 27 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2014
    RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 07 2014
    Rigel Announces First Quarter 2014 Financial Results May 07 2014
    Rigel Announces Webcast of Investor Day on May 6, 2014 Apr 30 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK